Tempus AI Stock What’s Changed After New Pharma Deals

Simply Wall St.01:13

Over the past week, Tempus AI disclosed multi-year collaborations with Pathos AI and Bristol Myers Squibb, plus EU IVDR certification for its xR assay, spanning oncology, neuroscience and data ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2678024102?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041","is_english":true,"pubTime":"2026-10-28 01:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2678024102","market":"us","top_or_hot":-1,"title":"Tempus AI Stock What’s Changed After New Pharma Deals","media":"Simply Wall St.","content":"<div>\n<p>Over the past week, Tempus AI disclosed multi-year collaborations with Pathos AI and Bristol Myers Squibb, plus EU IVDR certification for its xR assay, spanning oncology, neuroscience and data ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-stock-whats-changed-after-new-pharma-deals\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI Stock What’s Changed After New Pharma Deals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Stock What’s Changed After New Pharma Deals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-28 01:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-stock-whats-changed-after-new-pharma-deals><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past week, Tempus AI disclosed multi-year collaborations with Pathos AI and Bristol Myers Squibb, plus EU IVDR certification for its xR assay, spanning oncology, neuroscience and data ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-stock-whats-changed-after-new-pharma-deals\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEMT","symbol_name":"2倍做多TEM ETF-Tradr","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-stock-whats-changed-after-new-pharma-deals","article_id":"2678024102","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-stock-whats-changed-after-new-pharma-deals","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2678024102","pubTimestamp":1793121201,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Over the past week, Tempus AI disclosed multi-year collaborations with Pathos AI and Bristol Myers Squibb, plus EU IVDR certification for its xR assay, spanning oncology, neuroscience and data licensing worth $55 million over five years.\nThe combination of long-dated data agreements, expansion into neurological datasets and regulatory clearance for xR shifts Tempus AI’s revenue mix further toward recurring, high-visibility data and assay usage fees.\nInvestors will now be watching how Tempus...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEMT":"2倍做多TEM ETF-Tradr","BK4613":"AI应用软件","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4611":"AI医疗","BK4121":"生命科学工具和服务","ARKG":"ARK Genomic Revolution ETF","TEM":"Tempus AI","HEAL":"Global X HealthTech ETF","TEMC":"Corgi TEM 2x Daily ETF"},"translate_title":"Tempus AI 股票：新制药交易后发生了哪些变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEMT":0.6,"ARKG":0.6,"TEMC":0.6,"TEM":1.98,"HEAL":0.6},"content_text":"Over the past week, Tempus AI disclosed multi-year collaborations with Pathos AI and Bristol Myers Squibb, plus EU IVDR certification for its xR assay, spanning oncology, neuroscience and data licensing worth $55 million over five years. The combination of long-dated data agreements, expansion into neurological datasets and regulatory clearance for xR shifts Tempus AI’s revenue mix further toward recurring, high-visibility data and assay usage fees. Investors will now be watching how Tempus AI’s expanding Bristol Myers Squibb data partnerships could influence the company’s broader investment narrative and risk profile.  Scan beyond Tempus AI and see how other AI-driven healthcare players are positioned by running the hand-picked 34 healthcare AI stocks alongside this latest round of data and assay deals. AdvertisementTempus AI Investment Narrative Recap To own Tempus AI, you need to believe its large clinical and molecular data sets can become a durable, recurring software and diagnostics business rather than just a high-cost lab operation. The recent Pathos and Bristol Myers Squibb deals, plus EU IVDR clearance, support that thesis by pointing revenue toward multi-year data access and assay usage fees. The near term hinge still sits on execution toward sustainable cash generation while the company remains loss making, with net income at a loss of US$254.4 million on US$1.43b of revenue. Rising R&D, regulatory complexity and pharma budget risk remain the biggest near term threats if new contracts do not scale efficiently. The multi year Bristol Myers Squibb licensing agreement that runs through 2031 looks most relevant for near term catalysts. It deepens Tempus AI’s role in oncology drug development, tying its Lens platform and multimodal datasets directly into target discovery and clinical design work, which can support steadier engagement with a large pharma customer base. This type of long dated, data heavy contract can help cushion volatility in testing volumes, although execution risk stays high if competitive offerings pressure pricing or if BMS adjusts R&D priorities. For you as an investor, the key watchpoints are how quickly these agreements convert into recurring usage, and whether cost discipline keeps pace with that uptake. Tempus AI's current analyst framework points to US$2.6b in revenue and US$420.8 million in earnings by 2029. That scenario is based on 22.6% yearly revenue growth and an earnings change of about US$675 million from a loss of US$254.4 million today. Uncover why Tempus AI's fair value indicates a 10% potential upside to its current price, which could narrow quickly. NasdaqGS:TEM 1-Year Stock Price Chart Exploring Other Perspectives Some of the most optimistic analysts focus on Tempus AI’s push into higher margin software and dry lab services instead of reimbursement risk. Before this news, the bullish group was modeling about US$2.9b of revenue and US$11.1 million of earnings by 2029. You can compare that to the more cautious US$2.6b and US$420.8 million consensus view. Both camps built these stories before the new Bristol Myers Squibb and Pathos agreements, so opinions may evolve as fresh data rolls in. Explore 6 other Tempus AI fair value estimates, including one that suggests as much as 33% upside from the current price! Reach Your Own Conclusion Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider trusting your own analysis.  A great starting point for your Tempus AI research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision. See our latest analysis for Tempus AI. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Tempus AI's overall financial health at a glance.  Looking For More Investment Ideas Beyond Tempus AI? Once you have a view on Tempus AI, it often helps to compare it with a few very different opportunities side by side using the Simply Wall St Screener. That way you can see how risk, income potential and balance sheet strength line up against what you already own.  For investors who want higher risk with the possibility of meaningful upside, start by checking a focused list of 7 elite penny stocks with strong financials that already have stronger financial profiles than many tiny peers. If capital preservation and steadier business quality sit higher on your priority list, weigh Tempus AI against a curated group of 30 resilient stocks with low risk scores that screen well on our risk scoring. For those hunting for quality at a reasonable entry point, compare your thesis with a hand picked set of 21 high quality undiscovered gems that pair strong fundamentals with less market attention.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tempus AI might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2678024102","isCrawlerRequest":true}